Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1984 2
1985 1
1986 1
1987 4
1988 2
1989 7
1990 1
1991 3
1992 8
1993 1
1994 7
1995 10
1996 9
1997 6
1998 10
1999 12
2000 13
2001 7
2002 16
2003 12
2004 7
2005 13
2006 8
2007 8
2008 6
2009 4
2010 3
2011 14
2012 6
2013 4
2014 6
2015 10
2016 3
2017 2
2018 9
2019 11
2020 7
2021 8
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for bolus fa
Search for Bolun Fan instead (3 results)
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Haller DG, et al. J Clin Oncol. 2011 Apr 10;29(11):1465-71. doi: 10.1200/JCO.2010.33.6297. Epub 2011 Mar 7. J Clin Oncol. 2011. PMID: 21383294 Clinical Trial.
PURPOSE: This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with stage III colon cancer. ...The 3-year DFS rate was 70.9% with XELOX and 66.5% with FU/ …
PURPOSE: This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic a …
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Siegal DM, et al. N Engl J Med. 2015 Dec 17;373(25):2413-24. doi: 10.1056/NEJMoa1510991. Epub 2015 Nov 11. N Engl J Med. 2015. PMID: 26559317 Free article. Clinical Trial.
For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a meas …
For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus …
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
Aya, A. Rhodes, R. M. Grounds, N. Fletcher, M. Cecconi P167 - Fluid bolus practices in a large Australian intensive care unit B. Avard, P. ...Mebazaa P171 - Impact of fluid balance to organ dysfunction in critically ill patients C. Pereira, R. Marinho, R. Antunes, A. Marin …
Aya, A. Rhodes, R. M. Grounds, N. Fletcher, M. Cecconi P167 - Fluid bolus practices in a large Australian intensive care unit B. Avar …
The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Reduced sensitivity compared with lean animals.
Cusin I, Rohner-Jeanrenaud F, Stricker-Krongrad A, Jeanrenaud B. Cusin I, et al. Diabetes. 1996 Oct;45(10):1446-50. doi: 10.2337/diab.45.10.1446. Diabetes. 1996. PMID: 8826985
The effect of different doses of leptin, given as an intracerebroventricular (ICV) bolus, on body weight gain and food intake was investigated during refeeding, following a 24-h fast in lean (FA/fa) rats. ...More importantly, the effect of leptin was also obs …
The effect of different doses of leptin, given as an intracerebroventricular (ICV) bolus, on body weight gain and food intake was inv …
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
Douillard JY, Sobrero A, Carnaghi C, Comella P, Díaz-Rubio E, Santoro A, Van Cutsem E. Douillard JY, et al. Ann Oncol. 2003;14 Suppl 2:ii7-12. doi: 10.1093/annonc/mdg723. Ann Oncol. 2003. PMID: 12810451 Free article. Review.
Through the biochemical modulation of 5-fluorouracil (5-FU) with folinic acid (FA), the use of infusional rather than bolus regimens and the combination of 5-FU/FA with other active agents (notably irinotecan), first-line response rates (RRs) of 40% can be ac …
Through the biochemical modulation of 5-fluorouracil (5-FU) with folinic acid (FA), the use of infusional rather than bolus re …
Single intracerebroventricular bolus injection of a recombinant adenovirus expressing leptin results in reduction of food intake and body weight in both lean and obese Zucker fa/fa rats.
Muzzin P, Cusin I, Charnay Y, Rohner-Jeanrenaud F. Muzzin P, et al. Regul Pept. 2000 Aug 25;92(1-3):57-64. doi: 10.1016/s0167-0115(00)00150-6. Regul Pept. 2000. PMID: 11024566
A missense mutation of the leptin receptor induces hyperphagia and obesity in the obese Zucker fa/fa rat. Since the CNS is an important target of leptin action, we hypothesized that leptin gene transfer into the lateral cerebral ventricle could efficiently lead to i …
A missense mutation of the leptin receptor induces hyperphagia and obesity in the obese Zucker fa/fa rat. Since the CNS is an …
Beneficial effect of intravenous bolus of corticotropin-releasing factor on glucose intolerance of genetically obese (fa/fa) rats.
Rohner-Jeanrenaud F, Jeanrenaud B. Rohner-Jeanrenaud F, et al. Diabetes. 1992 Apr;41(4):493-8. doi: 10.2337/diab.41.4.493. Diabetes. 1992. PMID: 1607074
The effect of an ovine corticotropin-releasing factor (oCRF) bolus administered intravenously at the onset of glucose ingestion during oral glucose tolerance tests (OGTTs) was evaluated in conscious lean (FA/FA) and genetically obese (fa/fa) rat …
The effect of an ovine corticotropin-releasing factor (oCRF) bolus administered intravenously at the onset of glucose ingestion durin …
Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy.
Etienne MC, Guillot T, Milano G. Etienne MC, et al. Ann Oncol. 1996 Mar;7(3):283-9. doi: 10.1093/oxfordjournals.annonc.a010573. Ann Oncol. 1996. PMID: 8740793 Free article. Review.
However, there is no clear consensus about the optimal FU-FA schedule and dose. In addition, it would be of interest to identify FU-FA-responsive tumors. ...Considering the S-phase specificity of FU cytotoxicity as well as its rapid elimination from plasma, a schedu …
However, there is no clear consensus about the optimal FU-FA schedule and dose. In addition, it would be of interest to identify FU- …
Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer.
Sørbye H, Dahl O. Sørbye H, et al. Acta Oncol. 2003;42(8):827-31. doi: 10.1080/02841860310018972. Acta Oncol. 2003. PMID: 14968943 Clinical Trial.
This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer. Twenty-seven patients were treated every second week with oxaliplatin 85 mg/m2 as a 2-h infusion on …
This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line tr …
Where do we stand with 5-fluorouracil?
Schmoll HJ, Büchele T, Grothey A, Dempke W. Schmoll HJ, et al. Semin Oncol. 1999 Dec;26(6):589-605. Semin Oncol. 1999. PMID: 10606252 Review.
Due to the lack of other agents with significant activity, tremendous efforts have been undertaken to increase the efficacy of 5-FU by investigating alternative schedules of delivery and biomodulation. However, bolus 5-FU in combination with folinic acid (FA), eithe …
Due to the lack of other agents with significant activity, tremendous efforts have been undertaken to increase the efficacy of 5-FU by inves …
252 results